This innovation results in an elimination half-life of approximately 90 h (~4 days), supporting a once-weekly SC dosing regimen
No verifiable studies, no FDA approval, and no official institutional endorsements
It is used alongside diet and exercise for chronic weight management
(In fact, exendin-4 has to be cleared out through the kidneys, which takes time.) Successful clinical trials in humans were conducted in the early 2000s
Many professional women, just like you, come to me feeling frustrated and wondering why their GLP-1 journey isn't mirroring the rapid results they see on social media
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, also demonstrated significant efficacy in a phase II trial for MASH [6]